RARE-Bestpractices: a platform for sharing best practices for the management of rare diseases

Domenica Taruscio, Cristina Morciano, Paola Laricchiuta, Pierpaolo Mincarone, RARE-Bestpractices Consortium


Over the last decade the European Union has been coordinating actions addressing various aspects of rare diseases and has funded several cross-border research projects. Recently has initiated the biggest rare disease international collaborative effort by launching the International Rare Diseases Research Consortium (IRDiRC). RARE-Bestpractices is one of the more than 100 collaborative research projects on rare diseases funded under the Seventh Framework Programme for Research and Technological Development (FP7; 2007-2013) (1). As a wide, open and inclusive network, RARE-Bestpractices will build on the knowledge of the experts in rare disease research area and experts in guideline development and health technology assessment area, brought together, for the first time, from academic institutions, agencies, organizations, patient advocacy groups, governmental bodies. The project aims at building a platform to collect and exchange information on best practices for the management of rare diseases; to identify relevant research needs; to promote the development of high quality guidelines; and to contribute in making patients, health professionals and policy makers “informed guideline users”. Besides, RARE-Bestpractices will intend to define the extent to which conclusions from cost-effectiveness analyses for pharmaceuticals are accounted for and implemented in guidelines across a range of countries.


rare diseases, practice guidelines as topic, orphan drug production

Full Text:



European Commission. 2013. Rare Diseases. How Europe is meeting the challenges. Available from: http://ec.europa.eu/research/health/pdf/rare-diseases-how-europe-meeting-challenges_en.pdf

Aymé S., Rodwell C., eds., “2013 Report on the State of the Art of Rare Disease Activities in Europe”, July 2013. Available from: http://www.eucerd.eu/upload/file/Reports/2013ReportStateofArtRDActivities.pdf

Eurodis Factsheet “What is a rare disease”. Available from: http://www.eurordis.org/sites/default/files/publications/Fact_Sheet_RD.pdf

Taruscio D, Capozzoli F, Frank C. Rare diseases and orphan drugs. Ann. Ist. Super. Sanita. 2011;47 (1): 83-93.

Griggs RC, Batshaw M, Dunkle M, Gopal-Srivastava R, Kaye E, Krischer J, et al. Clinical research for rare disease: Opportunities, challenges, and solutions. Molecular Genetics and Metabolism. 2009;96(1):20-6.

European Parliament and the Council. Regulation (EC) 141/2000 of the European Parliament and of the Council of 16 December 1999 on orphan medicinal products. Official Journal 2000; L 18:1-5. 22/1.

Communication from the Commission to the European Parliament, the Council, the European Economic and Social Committee and the Committee of the Regions on Rare Diseases: Europe’s challenges (COM(2008)679 final)

European Council. Recommendation of 8 June 2009 on European action in the field of rare diseases. Official Journal C151: 7-10.

Directive 2011/24/EU of the European Parliament and of the Council of 9 March 2011on the application of patients’ rights in cross-border healthcare. L 88/45.

Abbott A. Rare-disease project has global ambitions. Nature. 2011;472(7341):17-.

IOM (Institute of Medicine). 2010. Rare Diseases and Orphan Products: Accelerating Research and Development. Washington, DC: The National Academies Press

Graham R, Mancher M, Miller Wolman D, Greenfield S, Steinberg E, eds. Clinical practice guidelines we can trust. National Academies Press, 2011

Terracciano L, Brozek J, Compalati E, Schünemann H. GRADE system: new paradigm. Curr Opin Allergy Clin Immunol. 2010 Aug;10(4):377-83.

Brouwers MC, Kho ME, Browman GP, Burgers JS, Cluzeau F, Feder G, et al. Development of the AGREE II, part 1: performance, usefulness and areas for improvement. Canadian Medical Association Journal. 2010;182(10):1045-52.

Brouwers MC, Kho ME, Browman GP, Burgers JS, Cluzeau F, Feder G, et al. Development of the AGREE II, part 2: assessment of validity of items and tools to support application. Canadian Medical Association Journal. 2010;182(10):E472-E8.

Brouwers MC, Kho ME, Browman GP, Burgers JS, Cluzeau F, Feder G, et al. The Global Rating Scale complements the AGREE II in advancing the quality of practice guidelines. Journal of Clinical Epidemiology. 2012;65(5):526-34.